Curcumin targets CXCL16-mediated podocyte injury and lipid accumulation in diabetic kidney disease treatment
- 28 November 2024
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 47 (12) , 924-939
Abstract
Among the complications of diabetes, diabetic kidney disease (DKD) frequently emerges, typified by the detrimental effects on renal function, manifesting through inflammation, dysregulated lipid metabolism, and harm to podocytes. Existing research underscores the significance of the soluble form of C-X-C chemokine ligand 16 (CXCL16) within the context of renal impairments. However, whether CXCL16 is involved in the pathogenesis of DKD remains elusive. We report that CXCL16 levels in the serum and kidneys of individuals with DKD were elevated and correlated with various lipid parameters. The expression of CXCL16 in human podocytes subjected to high glucose or palmitic acid induction and exogenous CXCL16 administration in these cells were examined. Higher CXCL16 levels were linked to abnormal lipid metabolism. Exogenous CXCL16 administration induced lipid droplets, microfilament disorganization, apoptosis, oxidative stress, and inflammation, inhibited PPAR γ, up-regulated COX2 expression, and inhibited Nrf2 translocation in podocytes. Molecular analysis revealed that Curcumin (Cur), a polyphenolic compound derived from Curcuma longa and an Nrf2 agonist, targets the ATP-binding pocket of CXCL16, inhibiting its kinase activity. Meanwhile, Cur therapy alleviated podocyte injury, lipid accumulation, improved glomerulopathy, and reduced albuminuria. Furthermore, after silencing CXCL16 expression in podocytes using siRNA, the effects of exogenous CXCL16 were nullified, and Cur no longer exhibited any significant impact. Thus, CXCL16 participates in the pathogenesis of DKD. Inhibition of CXCL16 has shown promising results in experimental models, suggesting its beneficial effects in ameliorating DKD.Keywords
Funding Information
- National Natural Science Foundation of China (82370719, 82204606, 82270761)
- Shanghai Pujiang Program (21PJ1412400)
- Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (ynms202205)
- Shanghai Sailing Program (22YF1441500)
- Budget Project of Shanghai University of Traditional Chinese Medicine (2021LK053)
- National Key Research and Development Program of China (2023YFC2411803)
- Leading Talent Program in Shanghai (058)
This publication has 44 references indexed in Scilit:
- NRF2 Regulates PINK1 Expression under Oxidative Stress ConditionsPLOS ONE, 2015
- Curcumin, an active component of turmeric (Curcuma longa), and its effects on healthCritical Reviews in Food Science and Nutrition, 2015
- CXCL16 in kidney and cardiovascular injuryCytokine & Growth Factor Reviews, 2014
- Curcumin decreases renal triglyceride accumulation through AMPK–SREBP signaling pathway in streptozotocin-induced type 1 diabetic ratsThe Journal of Nutritional Biochemistry, 2013
- Curcumin attenuates diabetic nephropathy by inhibiting PKC‐α and PKC‐β1 activity in streptozotocin‐induced type I diabetic ratsMolecular Nutrition & Food Research, 2011
- CXCL16 and oxLDL are induced in the onset of diabetic nephropathyJournal of Cellular and Molecular Medicine, 2009
- CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density LipoproteinThe American Journal of Pathology, 2009
- Curcumin inhibits cellular cholesterol accumulation by regulating SREBP-1/caveolin-1 signaling pathway in vascular smooth muscle cellsActa Pharmacologica Sinica, 2008
- Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE PathwayAnnual Review of Pharmacology and Toxicology, 2007
- CURCUMIN, THE ACTIVE PRINCIPLE OF TURMERIC (CURCUMA LONGA), AMELIORATES DIABETIC NEPHROPATHY IN RATSClinical and Experimental Pharmacology and Physiology, 2006